PYC Therapeutics (ASX:PYC) said it continues to progress towards its 48-month objective of becoming a commercial-stage drug developer under its published operational roadmap, according to a Thursday Australian bourse filing.
The focus for the firm now is to generate clinical proof-of-concept for each of its three clinical-stage drug candidates, per the filing.
The company will start with the presentation of phase one and two data for its lead blinding eye disease drug candidate in May, the filing said.
PYC Therapeutics' shares rose almost 6% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。